Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Case 6: - The man whom clozapine (Clozaril) could not touch
Published online by Cambridge University Press: 03 April 2024
Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Summary
Which of the following is true regarding clozapine (Clozaril) dosing?
Keywords
augmentationcombinationadjunctivetreatment resistanceschizoaffective disorderschizophreniabipolar disordertobacco use disorderplasma levelsadverse effectsclozapine (Clozaril)fluvoxamine (Luvox)lithium (Eskalith)aripiprazole (Abilify)olanzapine (Zyprexa)fluphenazine (Prolixin)ziprasidone (Geodon)risperidone (Risperdal)
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential Psychopharmacology , pp. 87 - 108Publisher: Cambridge University PressPrint publication year: 2024
References
Ashton, AK. Aripiprazole augmentation of clozapine: in refractory schizophrenia. Psychiatry (Edgmont) 2005; 2:18–19Google ScholarPubMed
Butler, MG. Pharmacogenetics and psychiatric care: a review and commentary. J Ment Health Clin Psychol 2018; 2:17–24CrossRefGoogle Scholar
Dhillon, N, Heun, R. Nocturnal enuresis is an under-recognised side effect of clozapine: results of a systematic review. Global Psychiatry 2019; 2:21–30Google Scholar
Ellison, JC, Dufresne, RL. A review of the clinical utility of serum clozapine and norclozapine levels. Ment Health Clin 2015; 5:68–73CrossRefGoogle Scholar
Gee, S, Howes, O. Optimising treatment of schizophrenia: the role of adjunctive fluvoxamine. Psychopharmacology 2016; 233:739–40CrossRefGoogle ScholarPubMed
Gray, J, Risch, S. When clozapine is not enough: augment with lamotrigine? Curr Psychiatry 2009; 8:40–6Google Scholar
Hinze-Selch, D, Deuschle, M, Weber, B, et al. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl) 2000; 149:163–9CrossRefGoogle ScholarPubMed
Kane, JM, Agid, O, Baldwin, ML, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry 2019; 80(2):18com12123CrossRefGoogle ScholarPubMed
Lammers, CH, Deuschle, M, Weigmann, H, et al. Coadministration of clozapine and fluvoxamine in psychotic patients – clinical experience. Pharmacopsychiatry 1999; 32:76–7CrossRefGoogle ScholarPubMed
Lu, ML, Lane, HY, Chen, KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000; 61:594–9CrossRefGoogle ScholarPubMed
Lu, ML, Lane, HY, Lin, SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004; 65:766–71CrossRefGoogle ScholarPubMed
Meyer, JM, Proctor, G, Cummings, MA, et al. Ciprofloxacin and clozapine: a potentially fatal but underappreciated interaction. Case Rep Psychiatry 2016; 2016:5606098Google ScholarPubMed
Meyer, JM, Stahl, SM. The Clozapine Handbook, Cambridge: Cambridge University Press, 2019CrossRefGoogle Scholar
Olsson, E, Edman, G, Bertilsson, L, et al. Genetic and clinical factors affecting plasma clozapine concentration. Prim Care Companion CNS Disord 2015; 17(1):10.4088/PCC.14m01704Google ScholarPubMed
Polcwiartek, C, Nielsen, J. The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology 2016; 233:741–50CrossRefGoogle ScholarPubMed
Schwartz, D. Interpretation of clozapine levels. Graylands Hospital Drug Bulletin 2017; 24:1–8Google Scholar
Stahl, SM. Stahl’s Essential Psychopharmacology: Prescriber’s Guide, 5. Cambridge: Cambridge University Press, 2017Google Scholar
Stahl, SM. Transporters, Receptors, and Enzymes as Targets of Psychopharmacological Drug Action, 5. Cambridge: Cambridge University Press, 2021Google Scholar
Stahl, SM, Schwartz, T. Case Studies: Stahl’s Essential Psychopharmacology. Cambridge: Cambridge University Press, 2016CrossRefGoogle Scholar
Tanzer, T, Warren, N, McMahon, L, et al. Treatment strategies for clozapine-induced nocturnal enuresis and urinary incontinence: a systematic review. CNS Spectr 2022; 28(2):133–44CrossRefGoogle Scholar
Wigard, ME, van Gool, AR, Schulte, PF. Addition of fluvoxamine to clozapine: theory and practice. Tijdschr Psychiatr 2013; 55:113–21Google ScholarPubMed